94 related articles for article (PubMed ID: 34411294)
1. A 2-year prospective analysis of insomnia as a mediator of the relationship between androgen deprivation therapy and perceived cognitive function in men with prostate cancer.
Garland SN; Savard J; Eisel SL; Wassersug RJ; Rockwood NJ; Thoms J; Jim HSL; Gonzalez BD
Cancer; 2021 Dec; 127(24):4656-4664. PubMed ID: 34411294
[TBL] [Abstract][Full Text] [Related]
2. Cognitive effects of long-term androgen deprivation therapy in older men with prostate cancer.
Pergolizzi D; Flaherty KR; Saracino RM; Root JC; Schofield E; Cassidy C; Katheria V; Patel SK; Dale W; Nelson CJ
Psychooncology; 2024 Mar; 33(3):e6336. PubMed ID: 38520472
[TBL] [Abstract][Full Text] [Related]
3. Effects of vortioxetine on hippocampal-related cognitive impairment induced in rats by androgen deprivation as a model of prostate cancer treatment.
Vaiana AM; Chen Y; Gelfond J; Johnson-Pais TL; Leach RJ; Ramamurthy C; Thompson IM; Morilak DA
Transl Psychiatry; 2023 Oct; 13(1):307. PubMed ID: 37788996
[TBL] [Abstract][Full Text] [Related]
4. Development of depression in patients using androgen deprivation therapy: A systemic review and meta-analysis.
Qazi SU; Altaf Z; Zafar M; Tariq MA; Khalid A; Kaleem A; Saad E; Qazi S
Prostate; 2024 May; 84(6):525-538. PubMed ID: 38372065
[TBL] [Abstract][Full Text] [Related]
5. Androgen Deprivation Therapy Unrelated to Alzheimer's Disease in the UK Biobank Cohort.
Lehrer S; Rheinstein PH
Anticancer Res; 2023 Jan; 43(1):437-440. PubMed ID: 36585167
[TBL] [Abstract][Full Text] [Related]
6. Vortioxetine Reverses Impairment of Visuospatial Memory and Cognitive Flexibility Induced by Degarelix as a Model of Androgen Deprivation Therapy in Rats.
Vaiana AM; Asher AM; Tapia K; Morilak DA
Neuroendocrinology; 2024; 114(3):279-290. PubMed ID: 38104552
[TBL] [Abstract][Full Text] [Related]
7. Treatment-Related Cognitive Impairment in Patients with Prostate Cancer: Patients' Real-World Insights for Optimizing Outcomes.
Cowan BA; Olivier K; Tombal B; Wefel JS
Adv Ther; 2024 Feb; 41(2):476-491. PubMed ID: 37979089
[TBL] [Abstract][Full Text] [Related]
8. Identification of distinct symptom profiles in prostate cancer patients with cancer-related cognitive impairment undergoing androgen deprivation therapy: A latent class analysis.
Liu Y; Yan Q; Zhou J; Yao X; Ye X; Chen W; Cai J; Jiang H; Li H
Asia Pac J Oncol Nurs; 2024 Jun; 11(6):100497. PubMed ID: 38845748
[TBL] [Abstract][Full Text] [Related]
9. Insomnia and creativity in Chinese adolescents: mediation through need for cognition.
Ren X; Shi M; Si S
BMC Psychol; 2024 Mar; 12(1):180. PubMed ID: 38553744
[TBL] [Abstract][Full Text] [Related]
10. Impact of androgen deprivation therapy on cognitive function in men with prostate cancer.
Yamamoto Y; Akashi Y; Kiba K; Hirayama A; Uemura H
BJUI Compass; 2024 Mar; 5(3):356-358. PubMed ID: 38481674
[No Abstract] [Full Text] [Related]
11. The role of anxiety and insomnia in the relationship between COVID-19 perseverative cognition and depression: Parallel and serial mediation analyses.
Lo HKY; Wang S; Chan JKN; Wong CSM; Wong GHS; Lei JHC; So YK; Fung VSC; Chu RST; Chung AKK; Lee KCK; Cheng CPW; Chan WC; Chang WC
Eur Neuropsychopharmacol; 2024 Apr; 84():18-19. PubMed ID: 38643695
[No Abstract] [Full Text] [Related]
12. Cardiovascular risk in ADT recipients: does the type of ADT matter?
Pinthus JH; Duivenvoorden WCM
Prostate Cancer Prostatic Dis; 2024 Apr; ():. PubMed ID: 38664503
[No Abstract] [Full Text] [Related]
13. The effect of chemotherapy on the exposure-response relation of abiraterone in metastatic castration-resistant prostate cancer.
Boerrigter E; Benoist GE; Overbeek JK; Donders R; Mehra N; van Oort IM; Ter Heine R; van Erp NP
Br J Clin Pharmacol; 2022 Mar; 88(3):1170-1178. PubMed ID: 34436788
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial.
Lopes RD; Higano CS; Slovin SF; Nelson AJ; Bigelow R; Sørensen PS; Melloni C; Goodman SG; Evans CP; Nilsson J; Bhatt DL; Clarke NW; Olesen TK; Doyle-Olsen BT; Kristensen H; Arney L; Roe MT; Alexander JH;
Circulation; 2021 Oct; 144(16):1295-1307. PubMed ID: 34459214
[TBL] [Abstract][Full Text] [Related]
15. Neurotoxicities of novel non-steroidal anti-androgens for prostate cancer: A systematic review and meta-analysis.
Bakouny Z; Yekedüz E; Braun DA; Berchuck JE; Hirsch L; Utkan G; Lee Y; Trinh QD; Choueiri TK; Ürün Y
Crit Rev Oncol Hematol; 2021 Oct; 166():103463. PubMed ID: 34461269
[TBL] [Abstract][Full Text] [Related]
16. Risk of Fracture During Androgen Deprivation Therapy Among Patients With Prostate Cancer: A Systematic Review and Meta-Analysis of Cohort Studies.
Wu CC; Chen PY; Wang SW; Tsai MH; Wang YCL; Tai CL; Luo HL; Wang HJ; Chen CY
Front Pharmacol; 2021; 12():652979. PubMed ID: 34421586
[No Abstract] [Full Text] [Related]
17. Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk.
Azad AA; Armstrong AJ; Alcaraz A; Szmulewitz RZ; Petrylak DP; Holzbeierlein J; Villers A; Alekseev B; Iguchi T; Shore ND; Gomez-Veiga F; Rosbrook B; Lee HJ; Haas GP; Stenzl A
Prostate Cancer Prostatic Dis; 2022 Feb; 25(2):274-282. PubMed ID: 34420037
[TBL] [Abstract][Full Text] [Related]
18. Psychosocial Factors Associated with Cognitive Function in Prostate Cancer Survivors on Hormonal Treatments: A Systematic Review.
Pembroke L; Sherman KA; Francis H; Dhillon HM; Gurney H; Gillatt D
Neuropsychol Rev; 2024 Apr; ():. PubMed ID: 38642173
[TBL] [Abstract][Full Text] [Related]
19. Androgen Deprivation Therapy for Prostate Cancer: Focus on Cognitive Function and Mood.
Reiss AB; Gulkarov S; Pinkhasov A; Sheehan KM; Srivastava A; De Leon J; Katz AE
Medicina (Kaunas); 2023 Dec; 60(1):. PubMed ID: 38256338
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
